文献速递乳房整形与再造美容整形

聚维酮碘与乳房植入物

Betadine and Breast Implants.
PubMed 文献 · Aesthet Surg J · 2018-01-01

2017年第四季度,美国FDA批准一家乳房植入物制造商修改使用说明,移除关于使用聚维酮碘(Betadine,10%聚维酮碘溶液,有效碘1%)的警告。此前2000年FDA曾担忧聚维酮碘会降解硅弹性体外壳。作者认为抗菌与生物膜控制策略是当代隆乳术的重要组成部分,有助于降低手术感染、包膜挛缩和乳房植入物相关间变性大细胞淋巴瘤(BIA-ALCL)的风险。

要点

  • 2017年第四季度FDA批准修改使用说明,移除聚维酮碘警告。
  • 聚维酮碘对革兰阳性和革兰阴性菌有理想抗菌谱。
  • 革兰阳性菌与包膜挛缩相关,革兰阴性皮氏罗尔斯顿菌与BIA-ALCL相关。

核心结论

  • 作者认为抗菌与生物膜控制策略是当代隆乳术的重要组成部分,有助于降低手术感染、包膜挛缩和BIA-ALCL的风险。
  • 作者认为整形外科医生应采取所有可行措施以提高乳房植入物结局质量并降低再手术率。

研究设计与样本

  • 本文为述评,基于美国FDA对乳房植入物制造商使用说明修改的审评与批准进行讨论。

主要发现

  • 2017年第四季度,美国FDA审评并批准一家乳房植入物制造商修改使用说明的请求,移除了关于使用聚维酮碘(10%聚维酮碘溶液,有效碘1%)的警告。
  • 2000年FDA曾担忧聚维酮碘会降解硅弹性体外壳。
  • 聚维酮碘对革兰阳性和革兰阴性菌有理想抗菌谱。
  • 革兰阳性菌与包膜挛缩相关,革兰阴性皮氏罗尔斯顿菌与BIA-ALCL相关。
  • 皮氏罗尔斯顿菌对氨基糖苷类抗生素耐药,但对至少50%聚维酮碘溶液敏感。

关键数值与推荐

  • 聚维酮碘为10%溶液,有效碘1%。
  • 皮氏罗尔斯顿菌对至少50%聚维酮碘溶液敏感。

临床怎么用

  • 原先超说明书使用的做法,现可被整形外科医生公开用于抗感染和生物膜控制策略。
  • 作者认为抗菌与生物膜控制策略是当代隆乳术的重要组成部分,有助于降低手术感染、包膜挛缩和BIA-ALCL的风险。
  • 作者认为整形外科医生应采取所有可行措施以提高乳房植入物结局质量并降低再手术率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the fourth quarter of 2017, the US FDA reviewed and approved a request by one of the breast implant manufacturers for a change in the Directions for Use (DFU) that removed warnings regarding the use of Betadine (povidone-iodine [PI] 10% solution, 1% available iodine [Purdue Frederick Company, Stamford, CT], also available in generic formulations [Aplicare, Inc., Meriden, CT]). Previously, in 2000, there were concerns by the FDA that PI would degrade the silicone elastomer shell. This change in the DFU represents an important advance that will benefit patients through the permitted use of PI to reduce the risk of bacterial contamination of implant surfaces. What was formerly an off-label practice can be openly practiced by plastic surgeons as an anti-infective and biofilm-mitigation strategy. PI has an ideal spectrum effect for gram-positive and gram-negative organisms. Gram-positive organisms have been linked to capsular contracture and gram-negative Ralstonia picketti to breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). R picketti is resistant to aminoglycoside antibiotics, but it is susceptible to at least a 50% solution of PI. We believe that the strategy of antisepsis and biofilm mitigation is an integral part of a contemporary approach for breast augmentation. This is beneficial regarding reduction of the risk of surgical infection, capsular contracture, and BIA-ALCL. Outcome data so far indicate that antibiotics/anti-infectives seem to reduce the incidence of these adverse events that lead to reoperation and increased costs. It behooves plastic surgeons to take all actionable steps that enhance the quality of breast implant outcomes and reduce the rate of reoperation.

来源:Aesthet Surg J,查看原文。版权归原作者所有。

引用

  1. Jewell ML, Adams WP. Betadine and Breast Implants. Aesthet Surg J. 2018. PMID: 29452341. doi:10.1093/asj/sjy044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。